Oryzon Genomics S.A. (0RDB.L)
EUR 2.74
(-1.44%)
EUR 2.74
(-1.44%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 15.39 Million USD | -5.6% |
| 2022 | 16.31 Million USD | 45.22% |
| 2021 | 11.23 Million USD | 2.23% |
| 2020 | 10.98 Million USD | -0.52% |
| 2019 | 11.04 Million USD | 48.61% |
| 2018 | 7.43 Million USD | 53.15% |
| 2017 | 4.85 Million USD | -0.59% |
| 2016 | 4.88 Million USD | -34.16% |
| 2015 | 7.41 Million USD | -59.69% |
| 2014 | 18.39 Million USD | 513.43% |
| 2013 | 2.99 Million USD | -23.94% |
| 2012 | 3.94 Million USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 4.21 Million USD | 0.0% |
| 2024 Q1 | - USD | 0.0% |
| 2023 Q2 | 8.02 Million USD | 0.0% |
| 2023 FY | - USD | -100.0% |
| 2023 Q1 | - USD | -100.0% |
| 2023 Q4 | - USD | 0.0% |
| 2023 Q3 | - USD | -100.0% |
| 2022 Q2 | 7.26 Million USD | 0.0% |
| 2022 Q1 | - USD | -100.0% |
| 2022 FY | 16.31 Million USD | 45.22% |
| 2022 Q4 | 16.31 Million USD | 0.0% |
| 2022 Q3 | - USD | -100.0% |
| 2021 Q3 | - USD | -100.0% |
| 2021 Q2 | 5.34 Million USD | 0.0% |
| 2021 FY | 11.23 Million USD | 2.23% |
| 2021 Q4 | 11.23 Million USD | 0.0% |
| 2021 Q1 | - USD | -100.0% |
| 2020 Q1 | 3.47 Million USD | 10.19% |
| 2020 FY | 10.98 Million USD | -0.52% |
| 2020 Q4 | 2.61 Million USD | 85.3% |
| 2020 Q3 | 1.41 Million USD | -28.15% |
| 2020 Q2 | 1.96 Million USD | -43.45% |
| 2019 FY | 11.04 Million USD | 48.61% |
| 2019 Q4 | 3.15 Million USD | 10.73% |
| 2019 Q2 | 2.54 Million USD | 30.47% |
| 2019 Q1 | 1.95 Million USD | -2.92% |
| 2019 Q3 | 2.84 Million USD | 11.94% |
| 2018 Q3 | 1.43 Million USD | -21.4% |
| 2018 Q4 | 2 Million USD | 39.72% |
| 2018 FY | 7.43 Million USD | 53.15% |
| 2018 Q2 | 1.82 Million USD | 5.72% |
| 2018 Q1 | 1.73 Million USD | 123.39% |
| 2017 Q2 | 1.4 Million USD | 24.25% |
| 2017 Q1 | 1.12 Million USD | -14.75% |
| 2017 Q4 | 774.58 Thousand USD | -25.79% |
| 2017 Q3 | 1.04 Million USD | -25.55% |
| 2017 FY | 4.85 Million USD | -0.59% |
| 2016 Q3 | 1.28 Million USD | 29.05% |
| 2016 FY | 4.88 Million USD | -34.16% |
| 2016 Q4 | 1.32 Million USD | 2.95% |
| 2016 Q2 | 996.28 Thousand USD | -16.84% |
| 2016 Q1 | 1.19 Million USD | -11.02% |
| 2015 Q4 | 1.34 Million USD | -1.64% |
| 2015 Q1 | 1.16 Million USD | 20.98% |
| 2015 Q2 | 3.4 Million USD | 191.99% |
| 2015 FY | 7.41 Million USD | -59.69% |
| 2015 Q3 | 1.36 Million USD | -59.75% |
| 2014 Q4 | 962.88 Thousand USD | -4.09% |
| 2014 Q2 | 6.8 Million USD | 0.0% |
| 2014 Q3 | 1 Million USD | -85.24% |
| 2014 FY | 18.39 Million USD | 513.43% |
| 2014 Q1 | 6.8 Million USD | 0.0% |
| 2013 FY | 2.99 Million USD | -23.94% |
| 2012 FY | 3.94 Million USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Boiron SA | 358.08 Million EUR | 95.7% |
| Laboratorios Farmaceuticos Rovi, S.A. | 483.34 Million EUR | 96.814% |
| Vetoquinol SA | 291.37 Million EUR | 94.715% |
| Valneva SE | 52.83 Million EUR | 70.857% |
| AB Science S.A. | 587 Thousand EUR | -2523.245% |
| Nanobiotix S.A. | 42.35 Million EUR | 63.647% |
| PHAXIAM Therapeutics S.A. | 1.32 Million EUR | -1061.271% |
| Vivoryon Therapeutics N.V. | -3.09 Million EUR | 597.527% |
| BioSenic S.A. | 543 Thousand EUR | -2735.81% |
| ABIVAX Société Anonyme | 3.91 Million EUR | -293.42% |
| Formycon AG | 23.3 Million EUR | 33.926% |